Skip to main content
Fig. 1 | BMC Ophthalmology

Fig. 1

From: Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

Fig. 1

Start dates of randomized controlled trials by indication. Legend: RCT start dates shown in relation to EMA and FDA ophthalmological marketing authorisation dates for Eylea®, Lucentis® and Macugen®. For sources of details and study periods for the RCTs see Additional file 2: Table S2. Abbreviations: BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; DME: diabetic macular oedema; EMA: European Medicines Agency; FDA: US Food and Drug Administration; nAMD: neovascular age-related macular degeneration; RCT: randomized controlled trial; RVO: retinal vein occlusion

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us